德尔塔
您当前所在位置:首页 > 宣传资料 > 材料科学 > 材料科学

「同位素标记抑制剂」Emedastine-13C,d3 fumarate

发布时间:2025-06-12     作者:德尔塔生物   分享到:

【产品介绍】:

生物活性:Emedastine-13C,d3 (fumarate) is the 13C- and deuterium labeled Emedastine. Emedastine is an orally active, selective and high affinity histamine H1 receptor antagonist with a Ki value of 1.3 nM. Emedastine is a benzimidazole derivative with potent antiallergic properties and used for allergic rhinitis, allergic skin diseases and allergic conjunctivitis[1][2][3].
体外研究(In Vitro):Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[67].
德尔塔生物 has not independently confirmed the accuracy of these methods. They are for reference only.
Emedastine-13C,d3 fumarate 相关抗体:
ADGRE1 (F4/80) Antibody (YA002)
ADGRE1 (F4/80) Antibody (YA920)
分子量:422.50
Formula:C2013CH27D3N4O5
非标记 CAS:87233-61-2
中文名称:依美斯汀富马酸盐-13C,d3; 依美司丁富马酸盐-13C,d3
运输条件:Room temperature in continental US; may vary elsewhere.
储存方式:Please store the product under the recommended conditions in the Certificate of Analysis.
纯度 & 产品资料
Data Sheet (536 KB)
产品使用指南 (1538 KB)
参考文献
[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-223.
 [Content Brief]
[2]. Sharif NA, et al. Emedastine: a potent, high affinity histamine H1-receptor-selective antagonist for ocular use: receptor binding and second messenger studies. J Ocul Pharmacol. 1994 Winter;10(4):653-64.
 [Content Brief]
[3]. Murota H, et al. Emedastine difumarate: a review of its potential ameliorating effect for tissue remodeling in allergic diseases. Expert Opin Pharmacother. 2009 Aug;10(11):1859-67.
 [Content Brief]
[4]. Andoh T, et al. Involvement of blockade of leukotriene B(4) action in anti-pruritic effects of emedastine in mice. Eur J Pharmacol. 2000 Oct 6;406(1):149-52.
 [Content Brief]